MOUNTAIN VIEW, Calif., Aug. 29 /PRNewswire-FirstCall/ -- Pharsight Corporation , a leading provider of software, strategic, and regulatory services for optimizing clinical drug development, today announced that there are now academic licenses for Pharsight software supporting over 3,500 students and teachers at more than 360 leading pharmacy and medical schools throughout the world.
“There continues to be a scarcity of scientific talent to perform industrial modeling and simulation,” said Shawn O’Connor, president, CEO, and chairman of Pharsight. “To help address this issue, Pharsight’s academic licensing program provides free licenses to the latest versions of our modeling and simulation tools for use by students and teachers. With over 3,500 students and teachers supported, this is a very large program. Our IVIVC Toolkit for WinNonlin has been recently added to our academic licensing program, and we are now supporting academic use in institutions in fast-growing emerging countries such as India, China, Korea, Taiwan, and Brazil.”
About Pharsight’s Academic Licensing Program
Pharsight’s Academic Licensing (PAL) program is designed to promote the academic, research, and educational use of Pharsight’s technology to reinforce its support of the evolving pharmaceutical engineering and pharmacometrics curricula at research and teaching establishments around the world. The PAL program supports students and teachers in the “traditional” drug development geographies of North America, Western Europe, and Japan, as well as emerging geographies.
Pharsight’s desktop products, WinNonlin(R), WinNonMix(R) and Trial Simulator(TM), are all available in the PAL program. Also included in the PAL program is IVIVC Toolkit(TM) for WinNonlin, which was released commercially in January 2007. IVIVC Toolkit is now licensed for use in 44 schools.
About Pharsight Corporation
Pharsight Corporation develops and markets integrated products and services that enable pharmaceutical and biotechnology companies to achieve significant and enduring improvements in the development and use of therapeutic products. The company’s goal is to help customers reduce the time, cost and risk of drug development, as well as optimize the post-approval marketing and use of pharmaceutical products.
Pharsight’s approach enhances the fundamental element of drug development success: strong decision-making. By adopting the Pharsight approach, customers acquire a new decision-making process with the potential to systematically improve every level and phase of their business and scientific processes. Pharsight is headquartered in Mountain View, California. Information about Pharsight is available at http://www.pharsight.com.
Forward Looking Statements
The statements in this press release related to the use of Pharsight software are forward looking statements. Forward-looking statements are inherently speculative, and actual results may differ materially from Pharsight’s expectations due to a variety of factors, including: changes in FDA regulations may affect the demand for the product; and customers may not perceive the benefits of the product to be the same as Pharsight believes them to be. Other risk factors relating to Pharsight are disclosed in the company’s most recent Form 10-Q filed with the Securities and Exchange Commission on August 13, 2007. All forward-looking statements are based on information available to the company on the date hereof, and the company assumes no obligation to update such statements.
Registered Trademarks and Trademarks
Pharsight, WinNonlin, WinNonMix, Trial Simulator, and IVIVC Toolkit for WinNonlin are trademarks or registered trademarks of Pharsight Corporation.
Pharsight Corporation
CONTACT: Investors, Jennifer Beugelmans, +1-646-201-5447, or DouglasSherk, +1-415-896-6820, or Media, Jennifer Saunders, +1-646-201-5431, allof EVC Group, for Pharsight Corporation
Web site: http://www.pharsight.com/
